Focus on an unusual rise in pancreatic cancer incidence in France

Bouvier, Anne–Marie; Uhry, Zoé; Jooste, Valérie; Drouillard, Antoine; Remontet, Laurent; Launoy, Guy; Léone, Nathalie

doi:10.1093/ije/dyx088

Cited by 50 publications

(28 citation statements)

References 19 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, two studies from Europe published in 2017 showed an increasing incidence trend in pancreatic cancer, and the study from France 23 also described diverging trends in pancreatic cancer incidence and mortality. 22 , 23 The incidence in both males and females increased during the past three decades, while mortality remained similar in men and slightly increased in women. 23 Several commentaries considered that these trends might be artificial.…”

Section: Discussionmentioning

confidence: 99%

Rising trends in pancreatic cancer incidence and mortality in 2000–2014

Yang

et al. 2018

CLEP

View full text Add to dashboard Cite

BackgroundThe morbidity and mortality of pancreatic cancer vary considerably around the world. The aim of this study was to characterize and evaluate recent changes in incidence and incidence-based mortality in the USA.MethodsIncidence and incidence-based mortality data were based on the 18 Surveillance, Epidemiology, and End Results (SEER) registries through SEER*Stat software. We adopted joinpoint regression to analyze the temporal trends stratified by age, gender, ethnicity, stage, tumor site, and size.ResultsBased on 18 SEER data sets, the age-adjusted incidence of pancreatic cancer increased from 11.85/100,000 in 2000 to 14.70/100,000 in 2014, increasing by an average annual percentage change (AAPC) of 1.6 (95% CI 1.5–1.8, p<0.05). The incidence-based mortality also increased, from 9.96/100,000 in 2001 to 12.96/100,000 in 2014, increasing by an AAPC of 1.9 (95% CI 1.3–2.5, p<0.05). However, we observed a deceleration in mortality since 2005, with the annual percentage change decreasing from 4.1 (2001–2005) to 1.0 (2005–2014). These increasing trends in pancreatic cancer were observed in most subgroups (stratified by age, gender, ethnicity, stage, tumor site, and size).ConclusionThe incidence and mortality rates of pancreatic cancer in the USA have increased significantly since 2000, highlighting the need for increased preventive, screening, and surveillance efforts.

show abstract

Section: Discussionmentioning

confidence: 99%

Rising trends in pancreatic cancer incidence and mortality in 2000–2014

Yang

et al. 2018

CLEP

View full text Add to dashboard Cite

show abstract

“…The incidence of pancreatic cancer (PC) has increased globally in the past decades. 1 , 2 , 3 About 55,440 new cases of PC are estimated in the USA in 2018, including 29,200 new cases in males and 26,240 female patients. 4 As a highly fatal malignance, PC has the lowest survival of human cancers; the 5-year relative survival rate only reaches 8%.…”

Section: Introductionmentioning

confidence: 99%

miR-7 Suppresses Tumor Progression by Directly Targeting MAP3K9 in Pancreatic Cancer

Xia

Cao

et al. 2018

Molecular Therapy - Nucleic Acids

View full text Add to dashboard Cite

Extensive research has suggested that miR-7 plays a critical role in cancer progression. However, the biological function of miR-7 in pancreatic cancer (PC) progression is poorly understood. Therefore, in the present study, we investigated the function of miR-7 and its molecular mechanism in PC progression. We used multiple methods, such as MTT, FACS, Transwell assay, RT-PCR, western blotting, and transfection to investigate the role of miR-7 in PC cells. We found that miR-7 suppressed cell growth, migration, and invasion but induced apoptosis in PC cells. Moreover, overexpression of miR-7 repressed tumor growth in mice, suggesting that miR-7 could exert its tumor-suppressive function in PC. Mechanistically, we validated that MAP3K9 is a direct target of miR-7, which significantly enhanced PC cell proliferation and inhibited cell apoptosis partly through activation of the MEK/ERK pathway and NF-κB pathway. Moreover, rescue experiments also showed that miR-7 suppressed PC cell proliferation and induced PC cell apoptosis by directly targeting MAP3K9, leading to inhibition of the MEK/ERK and NF-κB pathways. Taken together, these results suggest that miR-7/MAP3K9 is critically involved in PC progression and that miR-7 may be a potential target for PC treatment.

show abstract

“…In terms of the various birth cohorts (i.e. from 1920 to 1950), the probability of developing a pancreatic cancer before age 75 has increased [ 4 ]. The standard rate of mortality has of course increased in parallel, especially in women [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

“…from 1920 to 1950), the probability of developing a pancreatic cancer before age 75 has increased [ 4 ]. The standard rate of mortality has of course increased in parallel, especially in women [ 4 ]. These findings are alarming; a further increase in the incidence of pancreatic cancer is expected over the next 15 years in France regardless of age or gender.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A prospective clinical and biological database for pancreatic adenocarcinoma: the BACAP cohort

et al. 2018

View full text Add to dashboard Cite

BackgroundThe prognosis for pancreatic cancer remains poor despite diagnostic advances and treatments with new chemotherapeutic regimens. The five year survival rate remains below 3%. Consequently, there is an urgent need for new treatments to significantly improve the prognosis. In addition, there is a big gap in terms of the screening, early diagnosis and prevention of pancreatic cancer the incidence of which is increasing dramatically.MethodsDesign: the BACAP cohort is a prospective multicenter pancreatic cancer cohort (pancreatic ductal carcinoma) with clinical and multiple biological samples; Participating centers: 15 French academic and private hospitals; Study Population: any cytologically and/or histologically proven pancreatic carcinoma regardless of the stage (resectable, borderline, locally advanced or metastatic) or treatment (surgery, palliative chemotherapy, best supportive care). At least 1500 patients will be included. Clinical data collected include: disease presentation, epidemiological and social factors, baseline biology, radiology, endoscopic ultrasound, staging, pathology, treatments, follow-up (including biological and radiological), and survival. All these data are collected and stored through an e-observation system at a centralized data center. Biological samples and derived products (i.e. before any treatment): blood, saliva, endoscopic ultrasound-guided fine needle aspiration materials from the primary tumor, fine needle biopsy of metastases and surgically resected tissue. DNA and RNA are extracted from fine needle aspiration materials and are quantified and characterized for quality. Whole blood, plasma and serum are isolated from blood samples. Frozen tissues were specifically allocated to the cohort. All derived products and saliva are stored at − 80 °C. Main end-points: i) to centralize clinical data together with multiple biological samples that are harmonized in terms of sampling, the post sampling process and storage; ii) to identify new molecular markers for the diagnosis, prognosis and possibly the predictive response to pancreatic cancer surgery and or chemotherapy.DiscussionThe BACAP cohort is a unique prospective biological clinical database that provides the opportunity to identify correlations between the presence/expression of a broad panel of biomarkers (DNA, RNA, miRNA, proteins, etc.), epidemiological and social data, various clinical situations, various stages and the differentiation of the tumor, treatments and survival.Trial registrationClinicalTrials.gov Identifier: NCT02818829. Registration date: June 30, 2016.

show abstract

Focus on an unusual rise in pancreatic cancer incidence in France

Cited by 50 publications

References 19 publications

Rising trends in pancreatic cancer incidence and mortality in 2000–2014

Rising trends in pancreatic cancer incidence and mortality in 2000–2014

miR-7 Suppresses Tumor Progression by Directly Targeting MAP3K9 in Pancreatic Cancer

A prospective clinical and biological database for pancreatic adenocarcinoma: the BACAP cohort

Contact Info

Product

Resources

About

Focus on an unusual rise in pancreatic cancer incidence in France

Cited by 50 publications

References 19 publications

Rising trends in pancreatic cancer incidence and mortality in 2000&ndash;2014

Rising trends in pancreatic cancer incidence and mortality in 2000&ndash;2014

miR-7 Suppresses Tumor Progression by Directly Targeting MAP3K9 in Pancreatic Cancer

A prospective clinical and biological database for pancreatic adenocarcinoma: the BACAP cohort

Contact Info

Product

Resources

About

Rising trends in pancreatic cancer incidence and mortality in 2000–2014

Rising trends in pancreatic cancer incidence and mortality in 2000–2014